Table 3.
Number and proportion of women who developed cervical intraepithelial neoplasia grade 3 (CIN3) or worse during the entire follow-up period of 13.4 years in relation to human papillomavirus (HPV) type detected at baseline among cytologically normal Danish women*
| HPV species and type | Proportion developing CIN3 or worse during follow-up |
|||
| All women with the given HPV type | Women with the given HPV type alone | Women with the given HPV type plus other high-risk HPV types except HPV16 | Women with the given HPV type plus HPV16 with or without other high-risk HPV types | |
| N (%) | % | % | % | |
| Alpha 9 | ||||
| HPV16 | 75 (25.3) | 26.0 | 24.9 | NA |
| HPV31 | 40 (16.0) | 9.8 | 13.8 | 29.8 |
| HPV33 | 30 (18.3) | 12.8 | 12.8 | 41.9 |
| HPV35 | 7 (14.3) | 9.1 | 18.8 | 0 |
| HPV52 | 31 (12.6) | 4.7 | 14.7 | 17.4 |
| HPV58 | 14 (15.7) | 8.3 | 17.6 | 11.1 |
| Alpha 7 | ||||
| HPV18 | 21 (18.1) | 15.4 | 18.8 | 19.0 |
| HPV39 | 14 (10.1) | 0 | 9.0 | 28.6 |
| HPV45 | 12 (8.9) | 6.4 | 8.0 | 23.1 |
| HPV59 | 6 (9.5) | 0 | 6.5 | 50.0 |
| HPV68 | 5 (4.3) | 0 | 5.2 | 7.1 |
| Alpha 6 | ||||
| HPV53 | 6 (5.5) | 0 | 3.9 | 14.3 |
| HPV56 | 7 (5.7) | 2.3 | 7.7 | 4.8 |
| HPV66 | 14 (11.6) | 0 | 8.0 | 25.0 |
| Alpha 5 | ||||
| HPV51 | 16 (9.2) | 6.9 | 4.8 | 23.5 |
*
NA = not applicable.